-
Sector Analysis
Ovarian Cancer Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Ovarian Cancer Market Report Overview The ovarian cancer market across the 7MM was valued at $3.3 billion in 2022. The market will grow at a CAGR of more than 1% from 2022 to 2032. Ovarian cancer is one of the most lethal gynecological cancers worldwide. Each year in the US, more than 19,700 women receive a new diagnosis of ovarian cancer. Â The following are some of the key highlights of the ovarian cancer market: Report deliverables include a PowerPoint report...
-
Product Insights
Cervical Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Cervical Cancer Clinical Trials Analysis Market Overview A total of 2,108 Cervical Cancer clinical trials were conducted as of January 2024. The Cervical Cancer clinical trial report provides a comprehensive understanding of the Cervical Cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       ...
-
Sector Analysis
Colorectal Cancer in Major Markets by Drug Forecast, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Analysis to 2031
Colorectal Cancer Market Report Overview The colorectal cancer market sales across the 8MM were estimated at $15.8 billion in 2021. The market is expected to achieve a CAGR of more than 3% during 2021-2031. The anticipated approval and launch of 14 pipeline therapies and the label expansions of other agents drive the global colorectal cancer market growth. Colorectal cancer Market Outlook, 2021-2031 ($ Billion) Buy the Full Report to Know More about the Colorectal Cancer Market Forecast Download A Free...
-
Thematic Analysis
Biosimilars in Oncology - Thematic Intelligence
Accessing in-depth insights from the ‘Biosimilars in Oncology’ report will help you: Understand the milestones of biosimilars in oncology, the trends in the market, and the biosimilar value chain. Assess the marketed and pipeline products and their uptake across 8MM. Learn about the percentage of cancer patients treated with biosimilars, the price of the agents compared to their originator, and key opinion leaders’ outlook for the products. Examine the 8MM regulatory landscapes, their market potential, and their available and upcoming biosimilars....
-
Product Insights
Gallbladder Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Gall Bladder Cancer Clinical Trial Report Overview A total of 620 Gall Bladder Cancer clinical trials were conducted as of December 2023. The Gall Bladder Cancer clinical trial report provides a comprehensive understanding of the Gall Bladder Cancer clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
Hepatocellular Carcinoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Hepatocellular Carcinoma Clinical Trial Report Overview The total number of Hepatocellular Carcinoma clinical trials conducted as of December 2023 was 3,959. The Hepatocellular Carcinoma clinical trial report includes information about the sponsor type and the prominent sponsors associated with the Hepatocellular Carcinoma clinical trials. The report provides a comprehensive understanding of the Hepatocellular Carcinoma clinical trial scenario across regions and countries (G7 & E7), covering details on the various phases, trial status, and end points status. The Hepatocellular Carcinoma clinical...
-
Product Insights
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Waldenstrom Macroglobulinemia Clinical Trial Report Overview A total of 709 Waldenstrom Macroglobulinemia clinical trials were conducted as of December 2023. The Waldenstrom Macroglobulinemia clinical trial report provides a comprehensive understanding of the Waldenstrom Macroglobulinemia clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor type and the prominent sponsors associated with the trials. Key Regions ·       Asia-Pacific ·       Europe...
-
Sector Analysis
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Report Overview In 2023, the highest incident cases of Glioblastoma Multiforme (GBM) were from China and India. Glioblastoma Multiforme is a fast-growing and aggressive brain tumor. It is also referred to as a grade IV astrocytoma. GBM invades the nearby brain tissue but generally does not spread to distant organs. There are only a handful of innovator treatment options approved for the treatment of GBM and most conventional marketed drugs are small molecules,...
-
Sector Analysis
Anal Cancer (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Anal Cancer Marketed and Pipeline Drugs Market Overview Anal cancer develops in the cells and tissue of the skin lining on either the inside or outside of the anus. The development of anal cancer is directly linked to a complex inflammatory process secondary to infections such as (HPV) types 16 and 18. The progression of this inflammatory process heralds the development of anal intraepithelial neoplasia (AIN), or squamous cell carcinoma (SCC) in situ (Bowen disease), which is a pre-malignant condition....
-
Thematic Analysis
Digital Marketing Trends in Non-small Cell Lung Cancer
Digital Marketing Trends in Non-small Cell Cancer Report Overview Merck’s Keytruda.com achieved the highest total traffic across Non-small Cell Lung Cancer (NSCLC) patient sites in the US from October 2022 to September 2023. This was followed by BMS's Opdivo.com and AstraZeneca's Imfinzi.com. Keytruda.com was also supported by the most paid search engine optimization (SEO) at over 7,600 keywords, closely followed by Enhertu.com and Opdivo.com. Overall, the highest proportion of traffic to top branded patient NSCLC websites originated from direct and organic sources. The Digital...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.